Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics Limited has announced a change in the interest of its director, James Garner, with the acquisition of 5,000,000 unquoted options. These options were issued under the company’s Bonus Offer, as detailed in their prospectus filed with ASIC and ASX in early May 2025. This move reflects strategic financial adjustments and may influence the company’s market positioning and stakeholder interests.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 4,227,335
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.